Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy-A potential bladder sparing option for high risk non-muscle invasive bladder cancer

Photodiagnosis and Photodynamic Therapy

Volumn 7, Issue 4, 2010, Pages 213-220

  Lee, Lui Shiong ^a   Thong, Patricia Soo Ping ^b   Olivo, Malini ^b,c,d,e   Chin, William Wei Lim ^b   Ramaswamy, Bhuvaneswari ^b   Kho, Kiang Wei ^b   Lim, Pei Li ^a   Lau, Weber Kam On ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c AGENCY FOR SCIENCE   (Singapore)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bladder cancer; Lasers; Photodynamic therapy; Photosensitizers

Indexed keywords

BCG VACCINE; CHLORIN E6 POLYVINYLPYRROLDINE; FOTOLON; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLADDER CANCER; BLADDER CAPACITY; CANCER INVASION; CLINICAL ARTICLE; CYSTOSCOPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; FISTULA; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; PANCREAS CARCINOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; POVIDONE; PROTOPORPHYRINS; RADIATION-SENSITIZING AGENTS; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

FISTULA; MYCOBACTERIUM BOVIS BCG;

EID: 78649628873     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2010.08.005     Document Type: Article

References (30)

1. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002, 41:523-531.
2. Sylvester R.J., Van Der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-477.
3. Sylvester R.J., Van Der Meijden A., Witjes J.A., Jakse G., Nonomura N. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005, 66(Suppl 6a):90-107.
4. O'Donnell M.A., Lilli K., Leopold C., et al. For The National Bacillus Calmette-Guérin/Interferon Phase 2 Investigator Group: interim results from a national multicenter Phase II trial of combination Bacillus Calmette-Guérin plus interferon alpha-2b for superficial bladder cancer. J Urol 2004, 172:888-893.
5. Pinthus J.H., Bogaards A., Weersink R., Wilson B.C., Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol 2006, 175:1201-1207.
6. Jichlinski P. Photodynamic applications in superficial bladder cancer: facts and hopes!. J Environ Pathol Toxicol Oncol 2006, 25:441-451.
7. Nseyo U.O. Photodynamic therapy in the management of bladder cancer. J Clin Laser Med Surg 1996, 14:271-280.
8. Kausch I., Doehn C., Jocham D. Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer. Expert Rev Anticancer Ther 2006, 6:1301-1311.
9. Ramaswamy B., Manivasager V., Chin W.W., Soo K.C., Olivo M. Photodynamic diagnosis of a human nasopharyngeal carcinoma xenograft model using the novel Chlorin e6 photosensitizer Fotolon. Int J Oncol 2005, 26:1501-1506.
10. Chin W.W., Heng P.W., Bhuvaneswari R., Lau W.K., Olivo M. The potential application of chlorin e6-polyvinylpyrrolidone formulation in photodynamic therapy. Photochem Photobiol Sci 2006, 5:1031-1037.
11. Chin W.W., Lau W.K., Bhuvaneswari R., Heng P.W., Olivo M. Chlorin e6-polyvinylpyrrolidone as a fluorescent marker for fluorescence diagnosis of human bladder cancer implanted on the chick chorioallantoic membrane model. Cancer Lett 2007, 245:127-133.
12. Chin W.W., Lau W.K., Heng P.W., Bhuvaneswari R., Olivo M. Fluorescence imaging and phototoxicity effects of new formulation of chlorin e6-polyvinylpyrrolidone. J Photochem Photobiol B 2006, 84:103-110.
13. Chin W.W., Heng P.W., Olivo M. Chlorin e6-polyvinylpyrrolidone mediated photosensitization is effective against human non-small cell lung carcinoma compared to small cell lung carcinoma xenografts. BMC Pharmacol 2007, 7:15.
14. Istoin Y.P., Laptsevich T.P., Bizyuk S.A., Alexandrova E.N. Photodynamic efficacy of topical application of chlorin e6-polyvinyl pyrrolidone complex in tumor-bearing rats. Exp Oncol 2006, 28:299-302.
15. Korbelik M., Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 1999, 137:91.
16. Thong P.S., Ong K.W., Goh N.S., et al. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol 2007, 8:950-952.
17. Kessel D. Pharmacokinetics of N-aspartyl chlorin e6 in cancer patients. J Photochem Photobiol B 1997, 39:81-83.
18. Nseyo U., Shumaker B., Klein E.A., Sutherland K. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J Urol 1998, 160:39-44.
19. Waidelich R., Stepp H., Baumgartner R., Weninger E., Hofstetter A., Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001, 165:1904-1907.
20. Nathan T.R., Whitelaw D.E., Chang S.C., et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 2002, 168:1427.
21. McCaughan J.S., Ellison E.C., Guy J.T., et al. Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. Ann Thorac Surg 1996, 62:1009-1010.
22. Manyak M.J. Photodynamic therapy for urologic malignancies. AUA Update 1995, 12:94-104.
23. Lamm D., Brent A., Blumenstein, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta T1 and Carcinoma in Situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000, 163:1124-1129.
24. Uchibayashi T., Koshida K., Kunimi K., Hisazumi H. Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder. Br J Cancer 1995, 71:625-628.
25. Walther M.M., Delaney T.F., Smith P.D., et al. Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder. Urology 1997, 50:199-206.
26. Nseyo U.O., DeHaven J., Dougherty T.J., et al. Photodynamic therapy in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg 1998, 16:61-68.
27. Berger A.P., Steiner H., Stenzl A., Akkad T., Bartsch G., Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 2003, 61:338-341.
28. Waidelich R., Beyer W., Kuchel R., et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 2003, 61:332-337.
29. Manyak M.J., Ogan K. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J Endourol 2003, 17:633-639.
30. Shackley D.C., Briggs C., Gilhooley A., et al. Photodynamic therapy for superficial bladder cancer under local anesthetic. BJUI 2002, 89:665-670.